CJC-1295 for Fat Loss: Protocol, Dosing, and What to Expect
Evidence strength: moderate
What this protocol is for
Fat loss is a moderate use case for CJC-1295. The mechanism contributes: elevated GH and IGF-1 support lipolysis (the mobilisation of stored fat for energy use), preserve lean tissue during a calorie deficit, and improve recovery from the training that drives the deficit. But CJC is not a fat-loss tool in the way GLP-1 analogs are. It supports the cellular environment that fat loss happens in; it does not directly suppress appetite or alter glucose metabolism.
The clinical pattern in user reports tracks the mechanism. Body recomposition shifts (less fat, more or maintained lean tissue) over 8 to 12 weeks on a moderate calorie deficit plus consistent training. The combination produces results that diet and training alone often cannot match, particularly in men past 35 whose recomposition response has slowed. Anecdotally, users report the lean-tissue preservation effect is the more visible outcome: not dramatic scale weight drops, but a body composition shift toward leaner.
Used by many in the recovery / biohacking space alongside the diet and training work that drives the deficit. The peptide does not replace the deficit; it makes the body more efficient at partitioning the deficit toward fat rather than muscle. Run this as a tactical, legal performance layer in a recomp block, not as a standalone fat-loss protocol. For pure fat-loss firepower, GLP-1 analogs operate on different mechanisms and deliver more direct effects, with their own trade-offs.
Dose for fat loss
CJC-1295 with DAC: 1 to 2 mg subcutaneous once weekly. Without DAC (Mod GRF 1-29): 100 to 200 mcg per dose, 2 to 3 times daily. Pre-training timing is common for fat-loss protocols because the GH pulse aligns with the lipolytic window during exercise. Pre-sleep dosing supports overnight fat oxidation.
Cycle length
8 to 12 weeks aligned with a structured calorie deficit and training block. Running CJC without a paired deficit does not deliver fat loss; the peptide supports the environment but does not create the deficit. Cycle off for 4 to 6 weeks before another run.
Stack pairings
Commonly stacked with Ipamorelin and AOD-9604.
Expected timeline
Week 1–3: training recovery improves, hunger may actually increase (GH elevation can do this). Scale weight typically does not move dramatically in this window. Week 4–8: body composition shifts become visible. Lean tissue maintains or grows slightly even at calorie deficit; fat loss progresses faster than diet alone would predict. Week 8–12: cumulative recomp effect lands. Mirror change is more visible than scale change.
Common mistakes
- Treating CJC as a fat-loss drug rather than a recomp tool. The peptide supports lean-tissue preservation during a deficit; it does not replace the deficit. No deficit, no fat loss, regardless of the protocol.
- Stacking CJC with aggressive cutting diet without managing hunger. GH elevation can increase appetite. A diet that already has the user white-knuckling adherence may get worse before it gets better.
- Expecting GLP-1-level fat loss. Different mechanism, different outcomes. CJC is a body-composition tool; GLP-1s are appetite and metabolic tools. If raw fat loss is the only metric, CJC is not the strongest choice.
- Running CJC for fat loss without paired training. Lean tissue preservation during a deficit requires training stimulus. Without it, the body composition advantage of the protocol erodes.